SELLAS Life Sciences Group closed at $9.14 on Nov 4, up 3.04%, 40.9% below its 52-week closing high. Volume of 5.4M shares was 0.75× its 20-day average (below normal).
Split-adjusted performance: -19.4% over one month, +77.5% over six months, +410.6% over one year.
Short interest was 53.8M shares at the Oct 15 settlement, down 2.5% from the prior report (27.0% of float, 11.9 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| SLSSELLAS Life Sciences Group | $9.14 | +3.04% | +77.5% | — | — | — | $1.85B | |
| ZBIOZenas BioPharma | $28.46 | +0.28% | +36.6% | — | −11145.6% | — | $1.85B | Compare |
| AGIOAgios Pharmaceuticals | $31.38 | +0.58% | +16.3% | +259.3% | −225.1% | — | $1.87B | Compare |
| GENBGenerate Biomedicines | $14.16 | +2.24% | — | — | −1065.2% | — | $1.82B | Compare |
| BRVEBraveheart Bio | $20.11 | −6.01% | — | — | — | — | $1.81B | Compare |
| PGENPrecigen | $5.06 | −3.71% | +14.9% | +6322.7% | 36.5% | — | $1.81B | Compare |
| XERSXeris Biopharma Holdings | $10.46 | +1.06% | +64.2% | +28.7% | −33.8% | — | $1.91B | Compare |
| STOKStoke Therapeutics | $27.45 | +1.70% | −17.5% | +5.9% | −654.3% | — | $1.77B | Compare |
| NRIXNurix Therapeutics | $15.95 | −38.23% | −5.5% | +8426.3% | 81.7% | 5.9 | $1.74B | Compare |
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
